The clinical cases of ketoacidosis in patients with 2 type diabetes treated with inhibitors of sodium-glucose co-transporter

Diana Sh. Avzaletdinova , Ilmira Z. Khabibulluna , Olga Y. Ibragimova , Tatiana V. Morugova

For citation:

Abstract

The diabetic ketoacidosis (DKA) is the most frequent urgent condition in patients with diabetes mellitus which requires hospitalization and results to mortality. The most common causes of DKA are the presence of concomitant diseases in diabetic patients, as well as the violation of the insulin therapy regimen.
With the appearance of hypoglycemic drugs from the group of sodium-glucose co-transporter inhibitors (iSGLT2), isolated cases of DKA associated with their intake began to be recorded.
This article describes 4 cases of ketoacidosis in patients with type 2 diabetes mellitus and type 1 diabetes mellitus taking dapagliflozin which is a hypoglycemic drug from the group of inhibitors of the sodium-glucose co-transporter.
Key words: diabetes mellitus, ketoacidosis, sodium-glucose co-transporter inhibitors, dapagliflozin.

References

1. Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377 (7): 644–57. DOI: 10.1056/NEJMoa1611925
2. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373 (22): 2117–28. DOI: 10.1056/NEJMoa1504720
3. Mosley JF, Smith L, Everton E, Fellner C. Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management of Type-2 Diabetes. A Drug Class Overview 2015; 40: 451–62.
4. Vallon V, Platt KA, Cunard R et al. SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule. J Am Soc Nephrol 2011; 22 (1): 104–12. DOI: 10.1681/ASN.2010030246
5. Yang X-P, Lai D, Zhong X-Y et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta–analysis. Eur J Clin Pharmacol 2014; 70 (10): 1149–58. DOI: 10.1007/s00228-014-1730-x
6. Zhang M, Zhang L, Wu B et al. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta–analysis of randomized controlled trials. Diabetes Metab Res Rev 2014; 30 (3): 204–21. DOI: 10.1002/dmrr.2479
7. Liakos A, Karagiannis T, Athanasiadou E et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta–analysis. Diabetes, Obes Metab 2014; 16 (10): 984–93. DOI: 10.1111/dom.12307
8. Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab 2015; 100 (8): 2849-52. DOI: 10.1210/jc.2015–1884
9. Peters AL, Buschur EO, Buse JB et al. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care 2015; 38 (9): 1687-93. DOI: 10.2337/dc15–0843
10. Storgaard H, Bagger JI, Knop FK et al. Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment. Basic Clin Pharmacol Toxicol 2016; 118 (2): 168–70. DOI: 10.1111/bcpt.12457
11. Gelaye A, Haidar A, Kassab C et al. Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern. Case Reports Crit Care 2016; 2016: 1–3. DOI: 10.1155/2016/1656182
12. Rosenstock J, Ferrannini E. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors. Diabetes Care 2015; 38: 1638-42. DOI: 10.2337/dc15-1380
13. Hine J, Paterson H, Abrol E et al. SGLT inhibition and euglycaemic diabetic ketoacidosis. Lancet Diabetes Endocrinol 2015; 3 (7): 503-4. DOI: 10.1016/S2213-8587(15)00204-1
14. Анциферов М.Б., Квасников Б.Б. Первые результаты наблюдательного ретроспективного исследования по оценке эффективности применения дапаглифлозина у пациентов с сахарным диабетом 2 типа в реальной практике РФ (исследование GLORIA). Фарматека 2019; 26 (4): 36–45. [Antsiferov MB, Kvasnikov BB. The first results of an observational retrospective study assessing the effectiveness of the use dapagliflozin in patients with type 2 diabetes mellitus in real clinical practice in the Russian Federation (GLORIA study). Pharmateca 2019; 26 (4): 36–45 (in Russian)]. DOI: 10.18565/pharmateca.2019.4.36–45
15. Merovci A, Mari A, Solis C et al. Dapagliflozin lowers plasma glucose concentration and improves beta cell function. J Clin Endocrinol Metab 2015; 100 (5): 1927–32.
16. Халимов Ю.Ш., Агафонов П.В., Кузьмич В.Г. Роль и место дапаглифлозина в управлении сахарным диабетом 2-го типа: от теории к практике. Медицинский совет 2017; 3: 22–30. [Khalimov YS, Agafonov PV, Kuzmich VG. Role and place of dapagliflozin in the management of 2nd type diabetes: from theory to practice. Med Counc 2017; 3: 22-30 (in Russian)]. DOI: 10.21518/2079-701X-2017-3-22-30
17. Лебедев Д.А., Бабенко А.Ю. Применение ингибиторов натрий–глюкозного котранспортера 2-го типа: от результатов клинических исследований до практического применения в России. Медицинский совет 2018; 16: 100–6. [Lebedev DA, Babenko AY. Use of sodium-glucose co-transporter-2 inhibitors from clinical trial results to practical application in Russia. Med Counc 2018; 16: 100–8 (in Russian)]. DOI: 10.21518/2079-701X-2018-16-100-108
18. Смирнов В.В., Симаков А.В. Синдром гиперкетонемии у детей и подростков: патогенез, причины, диагностика. Лечащий врач. 2017-06-07. [Smirnov VV, Simakov AV. Sindrom giperketonemii u detei i podrostkov: patogenez, prichiny, diagnostika Lechashchii vrach. 2017-06-07 (in Russian)].

Портал CON-MED.RU:
https://con-med.ru/magazines/klinicheskiy_razbor_v_obshchey_meditsine/klinicheskiy_razbor_v_obshchey_meditsine-09-2021/sluchai_ketoatsidoza_na_fone_priema_sakharosnizhayushchikh_preparatov_iz_gruppy_ingibitorov_natriy_g/?bitrix_include_areas=Y

For citation:Avzaletdinova D.Sh., Khabibulluna I.Z., Ibragimova O.Y., Morugova T.V. The clinical cases of ketoacidosis in patients with 2 type diabetes treated with inhibitors of sodium-glucose co-transporter. Clinical review for general practice. 2021; 9: 24–32. DOI: 10.47407/kr2021.2.9.00104

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice